Umutekano n'akamaro k'ubuvuzi bwa B7-H3 bwibanda ku barwayi ba GBM basubiranye

Glioblastoma Multiforme (GBM) ni imwe muri kanseri zica cyane, kandi abarwayi hafi ya bose basubira kurwara GBM ukurikije uburyo busanzwe bwo kwivuza. GBM isubiramo (rGBM) igaragaza ko umuntu adashobora kubaho amezi 8 ariko nta buryo bwinshi bwo kuyivura.

TX103 ni umuti wo kuvura selile za CAR-T wibanda kuri B7-H3, wakozwe ku giti cye kandi wemewe n'amategeko y'Ubushinwa n'amahanga. Ibisubizo by'ibanze by'ubuvuzi bwa TX103 ku ndwara ya gliomas isubira byagaragajwe mu nama ngarukamwaka y'Umuryango w'Abanyamerika wita ku ndwara za kanseri (ASCO) mu 2024.(cyangwa seNCT05241392）.

Uburyo: Ubu ni ukwiyongera k'umuti mu buryo bufunguye, bukoreshwa mu kuboko kumwe, "3+3″ dose-winning-withdraw" no mu bushakashatsi butangwa mu buryo bwinshi. Intego y'ibanze kwari ugusuzuma umutekano n'umuti wihanganirwa cyane. Intego ya kabiri yari ugusuzuma ingaruka zo kurokoka, ibisubizo bya kanseri, ibisubizo by'ubudahangarwa bw'umubiri, n'ibipimo bya farumasi. Abarwayi bari hagati y'imyaka 18 na 75 banditswe kandi byemejwe ko bazongera kugaragara hakoreshejwe isuzuma ry'ishusho na B7-H3 expression >= 30% binyuze mu isesengura rya immunohistochemistry. TX103 yatanzwe mu barwayi mu kanwa cyangwa mu mvubura binyuze mu kigega cya Ommaya. TX103 yatangwaga buri cyumweru ku barwayi buri cyiciro ku rugero rwa dose ya 1, 2, na 3 (uturemangingo miliyoni 20, 60, 150, uko bikurikirana), hamwe n'ingendo enye nk'ingendo imwe.

Ibisubizo: Hagati ya Werurwe 2022 na Mutarama 2024, abarwayi 13 bahawe nibura inshinge imwe ya TX103 mu mutwe, aho abarwayi 3, 4, na 6 bari ku rugero rwa 1, 2, na 3. Umubare w’impinduka mu mikorere y’inshinge wari 4 (Ingufu nto, Ntarengwa 1,9). Abarwayi bose bashyizwe mu isesengura ry’umutekano, bagaragaje ko nta burozi bugabanya urugero cyangwa urupfu rujyanye n’ubuvuzi bwa CAR-T. Abarwayi bose bagize nibura ingaruka mbi imwe (AE), kandi AE zijyanye n’ubuvuzi (TRAEs) zari zirimo cytokine release syndrome, kwiyongera k’umuvuduko mu mutwe (ICP), kuribwa umutwe, igicuri, kugabanuka k’ubwenge, kuruka, no gushyuha. TRAE nyinshi zari ku rwego rwa 1-2, mu gihe TRAE eshatu zo mu rwego rwa 3 zagaragaye: umuntu umwe wiyongereye ICP mu rugero rwa 2, umuntu umwe w’igicuri, n’undi muntu wiyongereye k’ubwenge mu rugero rwa 3. Guhera muri Mutarama 2024, abarwayi batandatu bo ku rwego rwa 1 na 2 bari bemerewe isuzuma ry’ubuzima bwabo bw’amezi 12; Igipimo cy’amezi 12 yo kubaho (OS) cyari 83.3% (95% CI: 58.3% ~ 100%), naho igipimo cy’imikorere y’umubiri (OS) cyari amezi 20.3 (95% CI: 20.3 ~ ntikigera ku murwayi). Babiri muri batatu bo ku rwego rwa 2 rw’umuti batanze ibisubizo by’igice n’ibyuzuye, uko bikurikirana. Nyuma yo guhabwa CAR-T, ubwiyongere bugaragara bwa cytokines, harimo IL-6 na IFN-γ, hamwe n’umubare munini wa kopi ya gene ya CAR byagaragaye mu mazi yo mu bwonko, mu gihe ubwiyongere buke bwagaragaye mu maraso yo mu gice cy’umugongo.

Umwanzuro: Muri iri gerageza, kuvura rGBM na TX103 bifatwa nk'aho ari byiza kandi byihanganirwa. Ibi bisubizo by'agateganyo bishyigikira inyigo irambuye ikoreshwa rya TX103 kugira ngo hongerwe umusaruro w'ubuzima ku barwayi ba rGBM.

Kuri ubu, hari andi magerageza menshi ya CAR-T mu Bushinwa, kandi barimo gushaka abarwayi. Kugira ngo ubone inama ku miti mishya n'ikoranabuhanga, ushobora kuvugana n'Ishami Mpuzamahanga ry'Ibitaro bya Oncology bya Beijing Region South.

Nimero ya Terefone: 4008803716

Email：myimmnet@163.com